Search

Displaying results 3561 - 3570 of 7186 in total
  1. Drug

    Difluocortolone

    go.drugbank.com/drugs/DB09095
    ApprovedWithdrawn

    It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]

  2. Drug

    Rasagiline

    go.drugbank.com/drugs/DB01367
    ApprovedInvestigational

    Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.

    Synonyms: (1R)-N-propargylindan-1-amine, (R)-N-2-Propynyl-1-indanamineCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Roquinimex

    go.drugbank.com/drugs/DB11366
    Experimental

    Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.

  4. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    [L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]

  5. Drug

    Deserpidine

    go.drugbank.com/drugs/DB01089
    ApprovedWithdrawn

    Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure

  6. Drug

    Tesamorelin

    go.drugbank.com/drugs/DB08869
    ApprovedInvestigational

    Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.

    Synonyms: N-[(3E)-1-oxo-3-hexenyl]Somatoliberin (human pancreatic islet)
  7. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  8. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. … It was being developed by Anesiva, but trials have halted.

  9. Drug

    Binimetinib

    go.drugbank.com/drugs/DB11967
    ApprovedInvestigational

    [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients … with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.

  10. Drug

    Valinomycin

    go.drugbank.com/drugs/DB14057
    Experimental

    A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. … It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring.